'Bugs as drugs' approach to cancer nears advanced development, Informa Pharma Intelligence, 19 January 2022
4D pharma's appointment of John Doyle as Chief Financial Officer
Microbiome Drugs: Multiplying Recent Gains, Genetic Engineering & Biotechnology News (GEN), 5 January 2022
Developing and delivering live biotherapeutic products, European Pharmaceutical Review, 4 November 2021
4D pharma Q&A: the potential of gut bacteria in cancer and beyond, Pharmaceutical Technology, 1 October 2021
Living Biotherapeutics Explore New Niches, Genetic Engineering & Biotechnology News (GEN), 2 August 2021
4D pharma Announces Publication of Preclinical Research Showing Single Strain Megasphaera massiliensis improves activity of CAR-T, 6 July 2021
Microbiome-targeting pipeline addresses multiple immunological indications, GlobalData / Clinical Trials Arena, 2 July 2021
A report by biopharma industry research firm GlobalData on the microbiome therapeutics field, highlights the truly unique and major market opportunity for 4D pharma's Blautix (MRx1234) as the first product capable of treating both IBS-C and IBS-D subtypes, and the potential to capture "exclusive market share of IBS-M" which accounts for around 30% of IBS patients for whom there are currently no approved products in US or Europe.
CEO Duncan Peyton spoke to BioPharma Reporter about 4D pharma's continued progress and expanding clinical activities in key areas such as oncology, asthma and neurodegenerative disease.
Live biotherapeutics change the pharma landscape, MedNous, June 2021
Article focusing on 4D pharma's clinical strategy for Live Biotherapeutics in oncology, also touches on 4D's leading manufacturing capabilities. Download a copy here.
Microbiome therapeutics rising as potential immuno-oncology agents, Clinical Trials Arena & GlobalData, 9 June 2021
Clinical data and industry partnerships have fueled a shift in perception of the microbiome-based therapeutic market from nascent to developing, with GlobalData forecasting the market to be worth $1.554B in 2026.
4D pharma presents additional positive data from Phase II trial of Blautix for irritable bowel syndrome at Digestive Disease Week (DDW) 20201
Fecal microbiota potentiate checkpoint inhibitors, unleash microbiome startups, Nature Biotechnology, 16 April 2021
Coverage of 4D pharma's two clinical collaborations with lead immuno-oncology LBP MRx0518
Companies Merging With SPACs Face Challenges Around Valuations, Controls, The Wall Street Journal, 13 April 2021
CEO Duncan Peyton spoke to the Wall Street Journal about adding financial expertise to our Board in the lead up to our Nasdaq listing
Completion of Merger with Longevity, launch of NASDAQ listing and concurrent fundraising
CEO Duncan Peyton spoke with Evaluate about the attractiveness of a SPAC as a route to a US listing.
4D Pharma Joins The SPAC Trend To Fund Its Keytruda-Boosting Biotherapeutic, Scrip Informa Pharma Intelligence, 17 February 2021
Scrip's Andrew McConaghie speaks to 4D CEO Duncan Peyton about the upcoming NASDAQ listing, what this means for 4D and its pipeline of Live Biotherapeutics including lead immuno-oncology candidate MRx0518.
4D pharma enters clinical collaboration with Merck KGaA and Pfizer
4D announces a clinical collaboration and drug supply agreement with Merck KGaA and Pfizer, combining 4D's MRx0518 with BAVENCIO® (avelumab) as a first-line maintenance therapy for patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.
Nature's Biophara Dealmakers publication offers an overview of the rapidly growing microbiome field, with increasing amounts of investment and partnering interest, driven by leaders like 4D pharma.
Updates on MRx0518 + pembro in patients with resistance to therapy, Video Journal of Oncology, 27 November 2020
CSO Dr Alex Stevenson discusses the data for immuno-oncology Live Biotherapeutic MRx0518 presented at SITC2020, showing positive activity on tumor immune infiltration, systemic immune signals and tumor gene expression, all associated with anti-cancer activity. This data demonstrates the contribution of MRx0518 to the remarkable clinical efficacy seen in combination with immune checkpoint inhibitor Keytruda (pembrolizumab), and the extensive opportunities for future development of MRx0518.
CEO Duncan Peyton speaks to ShareBuyers about recent positive IBS results, 4D's upcoming NASDAQ listing in early 2021, and what’s next for 4D
US listing set to support and accelerate ongoing development of 4D Pharma’s live biotherapeutics, BioPharma Reporter, 3 November
CEO Duncan Peyton speaks to BioPharma-Reporter about what the Longevity (NASDAQ: LOAC) merger and NASDAQ listing mean for 4D pharma
Gut feeling: why microbiomes holds so much promise for targeted therapeutics, Drug Discovery World, 3 November 2020
4D pharma spoke to Lu Rahman about the growing significance of microbiomics in the quest for new therapeutics
4D pharma announces merger with Longevity SPAC and intention to list on NASDAQ, 22 October 2020
The Medicine Maker takes a deep dive into 4D pharma and its functionality-driven approach to Live Biotherapeutic development, including manufacturing, regulation, and the huge potential for the field in the near future
Going for growth! 4D pharma: the pioneering live biotherapeutics trailblazer ready to realise its true value, 15 September 2020
4D pharma is featured in Sharebuyers' Going For Growth series, spotlighting companies which have shown strong growth potential in recent months. We discuss the significant opportunities presented by Live Biotherapeutics and 4D's leading position, some of the unique challenges, and a number of exciting growth catalysts on the horizon
Revolutionary new medicines from the human gut microbiome, Nature Biopharma Dealmakers, 1 September 2020
4D pharma's programs in oncology (MRx0518 and neurodegenerative disease (MRx0029 & MRx0005), feature in Nature BioPharma DealMakers. View online via the link above, or download the PDF
CEO Duncan Peyton talks with Proactive's Katie Pilbeam about 4D's positive clinical benefit data for lead immuno-oncology candidate MRx0518 in combination with immune checkpoint inhibitor Keytruda
Also covered by Proactive Investors' Ian Lyall
4D's CEO Duncan Peyton discusses the advantages of 4D's unique approach to Live Biotherapeutics with Proactive Investors
Watch Proactive Investor's Andrew Scott interview 4D's CEO, Duncan Peyton, discussing the company's recent progress in the clinic in oncology and IBS, its Phase II clinical trial in COVID-19, and more
4D pharma receives MHRA approval for Phase II COVID-19 trial
BioSpace: 4D pharma Presents Additional Interim Clinical Data From Combination Study for Lead Oncology Candidate, 17 March 2020
4D presents additional data from its ongoing Phase I/II trial of LBP MRx0518 in combination with Keytruda® at Chardan's virtual 2nd Annual Microbiome Medicines Summit